# October 6, 2026 — scheduled research update [Home](../README.md) · [Latest](../LATEST.md) · [Milestones](../MILESTONES.md) Focused review of all 32 active condition topics in six groups. The preserved Sleep hub is historical coverage, not a duplicate assignment. Named-program checks and overlap discovery include September 5/6 onward, prioritizing additions since the last focused runs. All broad-topic reviews remain partial: successful-check timestamps are preserved. Source dates, historical baselines, forecasts, registry estimates and rumors remain distinct. ## Findings - **2026-10-05 — Sponsor-reported open-label extension and conference data:** [Deramiocel extension reports slower upper-limb decline after placebo crossover](../topics/04_muscle.md#note-2026-10-05-deramiocel). - **2026-10-02 — Sponsor regulatory announcement, syndicated original release:** [Lorecivivint application validated for European review](../topics/11_joint_preservation.md#note-2026-10-02-lorecivivint). - **2026-01-14 — Historical baseline; Historical human-trial registration, current October 6 record:** [Recovered baseline: CARTISTEM has a recruiting U.S. phase 3 study](../topics/11_joint_preservation.md#note-2026-01-14-cartistem). - **2026-10-02 — New human phase 1 registration:** [South Korean childhood-onset lupus CAR-T study enters the registry](../topics/15_autoimmune.md#note-2026-10-02-snuh). - **2026-08-08 — Historical baseline; Peer-reviewed historical phase 4 single-arm study:** [Recovered baseline: small postoperative suzetrigine study lacks a control arm](../topics/16_pain.md#note-2026-08-08-suzetrigine). - **2026-10-02 — New phase 4 human-trial registration:** [New randomized study tests suzetrigine after urogynecologic surgery](../topics/16_pain.md#note-2026-10-02-suzetrigine). - **2026-09-30 — Peer-reviewed phase 2a randomized trial abstract; full text unavailable:** [Small peanut-immunotherapy trial misses abatacept’s primary immune endpoint](../topics/26_allergy_airway.md#note-2026-09-30-abatacept). - **2026-10-05 — New human phase 3 registration:** [Adolescent asthma study registers a triple-inhaler comparison](../topics/26_allergy_airway.md#note-2026-10-05-chf5993). - **2026-10-05 — Sponsor-only randomized phase 3 topline and SEC-filed slides:** [VAX-31 meets primary immune-response endpoints, with a comparator-specific caveat](../topics/27_infectious_disease.md#note-2026-10-05-vax31). - **2026-10-05 — New human phase 2b registration:** [TNP-2092 adds an intra-articular infected-prosthesis trial](../topics/27_infectious_disease.md#note-2026-10-05-tnp2092). - **2026-10-06 — New human phase 3 registration of an already started study:** [China registers a large placebo-controlled RSV-vaccine trial](../topics/27_infectious_disease.md#note-2026-10-06-rsv). - **2026-09-29 — Peer-reviewed phase 3 primary abstract; full-text access gap:** [TRIUMPH-1 publication adds OSA and knee-pain substudies](../topics/03_glp1.md#note-2026-09-29-triumph1). - **2026-10-06 — New phase 3 trial registration:** [Zenagamtide registers an 8,500-person cardiovascular-outcomes trial](../topics/07_cardiovascular.md#note-2026-10-06-ambience). - **2026-10-02 — New randomized screening-management trial registration:** [REFINE-CAC will test how AI plaque disclosure changes preventive care](../topics/07_cardiovascular.md#note-2026-10-02-refinecac). - **2026-10-01 — Peer-reviewed randomized placebo-controlled mechanistic trial:** [REMODEL reports null primary MRI comparisons alongside secondary kidney signals](../topics/17_kidney.md#note-2026-10-01-remodel). - **2026-09-30 — New randomized trial registration:** [New trial tests finerenone plus semaglutide in non-diabetic CKD](../topics/17_kidney.md#note-2026-09-30-finerenonesemaglutide). - **2026-09-30 — New trial registration:** [Zigakibart–atrasentan phase 3 combination study is registered](../topics/17_kidney.md#note-2026-09-30-zigakibartatrasentan). - **2026-10-05 — Newly posted registry; actual start predates registration:** [CKD risk-alert study tests whether outreach accelerates screening](../topics/17_kidney.md#note-2026-10-05-ckdrisk). - **2026-10-02 — Sponsor presentation announcement:** [SCD-PED pediatric AKI registry comparison is scheduled for October 22](../topics/17_kidney.md#note-2026-10-02-scdped). - **2026-10-06 — New trial registration:** [ARO-INHBE adds a randomized MASH phase 2 plan](../topics/13_liver.md#note-2026-10-06-aroinhbe). - **2026-10-02 — New phase 3 trial registration:** [ALN-CIDEB registers a large MASLD study with primary safety endpoints](../topics/13_liver.md#note-2026-10-02-alncideb). - **2026-09-23 — Historical baseline; Baseline addition from primary registry:** [Older rapamycin cardiac MRI substudy has an October completion estimate](../topics/05_longevity.md#note-2026-09-23-rapamycinmri). - **2026-10-06 — Informal claim and source-chain verification:** [PEARL 24-month claim cites an unrelated cellular-aging paper](../topics/05_longevity.md#note-2026-04-11-pearl24month). - **2026-09-28 — New registry recovered from overlap search:** [DARI-DREAM registration resolves the missing daytime-function study identifier](../topics/29_sleep_insomnia.md#note-2026-09-28-daridream). - **2026-10-05 — Registry recruitment/actual-start update:** [COMISA-PEC begins studying daridorexant before CPAP](../topics/29_sleep_insomnia.md#note-2026-10-05-comisapec). - **2026-08-18 — Historical baseline; Peer-reviewed exploratory randomized trial; PubMed XML/abstract:** [Small digital CBT-I versus zolpidem trial is older baseline context](../topics/29_sleep_insomnia.md#note-2026-08-18-sleepymed). - **2026-10-06 — Historical baseline; Older program baseline and current registry status:** [MARITIME-OSA-1 is active with enrollment closed in its current record](../topics/30_sleep_apnea.md#note-2026-10-06-maritimeosa1). - **2026-10-02 — Historical baseline; Historical program baseline from two primary registries:** [Cleminorexton SAPPHIRE adds an orexin-agonist development baseline](../topics/31_sleep_hypersomnolence.md#note-2026-10-02-cleminorexton). - **2026-09-18 — Historical baseline; Historical development baseline from primary registries:** [TAK-360 adds separate NT2 and idiopathic-hypersomnia trial baselines](../topics/31_sleep_hypersomnolence.md#note-2026-09-18-tak360). - **2026-07-27 — Historical baseline; Older phase 3 baseline from registry:** [Tasimelteon delayed-phase trial has an elapsed completion estimate](../topics/32_sleep_circadian.md#note-2026-07-27-tasimelteondswpd). - **2026-07-24 — Historical baseline; Older randomized phase 3 baseline:** [SUSTAIN tests solriamfetol for shift-work sleepiness](../topics/32_sleep_circadian.md#note-2026-07-24-sustain). - **2026-09-16 — New phase 2 trial registration:** [New refractory-RLS trial compares immediate with delayed IV iron](../topics/33_sleep_restless_legs.md#note-2026-09-16-rlsiron). - **2026-06-30 — Historical baseline; Older recruiting device-optimization baseline:** [Extended-duration TOMAC study targets RLS-related awakenings](../topics/33_sleep_restless_legs.md#note-2026-06-30-xdtomac). - **2026-09-16 — Peer-reviewed observational abstract; full methods unavailable:** [Venous-ablation RLS report is an uncontrolled association](../topics/33_sleep_restless_legs.md#note-2026-09-16-rfa). - **2026-10-01 — Peer-reviewed systematic review and meta-analysis of human screening cohorts:** [Whole-body MRI review quantifies findings and workups; patient benefit remains unknown](../topics/01_whole_body_mri.md#whole-body-mri-review-quantifies-findings-and-workups-patient-benefit-remains-unknown). - **2026-10-05 — Sponsor announcement of scheduled conference analyses; no new appraised readout:** [Galleri adds October presentations on repeat screening, equity and diagnostic-workup safety](../topics/02_galleri.md#galleri-adds-october-presentations-on-repeat-screening-equity-and-diagnostic-workup-safety). - **2026-10-05 — Peer-reviewed prospective randomized diagnostic-strategy trial; retrospective registration:** [Genome sequencing increases diagnostic yield in a developmental-disorder trial, with an adjusted uncertainty](../topics/28_genetic_screening.md#genome-sequencing-increases-diagnostic-yield-in-a-developmental-disorder-trial). - **2026-09 — Historical baseline; Sponsor modeling whitepaper; recovered historical baseline, not new clinical news:** [Recovered Nucleus whitepaper clarifies modeled embryo-score spreads](../topics/28_genetic_screening.md#recovered-nucleus-whitepaper-clarifies-modeled-embryo-score-spreads). - **2026-09-24 — Peer-reviewed randomized phase 3 final secondary-endpoint analysis; primary abstract appraised:** [Final IMpassion050 follow-up finds no significant event-free or disease-free benefit](../topics/14_cancer_vaccines.md#final-impassion050-follow-up-finds-no-significant-event-free-or-disease-free-benefit). - **2026-10-02 — Original Reddit timing inference, unconfirmed:** [Speculation — unconfirmed: REGAL’s final-analysis trigger is imminent](../topics/14_cancer_vaccines.md#speculation-unconfirmed-regals-final-analysis-trigger-is-imminent). - **2026-10-01 — Peer-reviewed critical appraisal and reanalysis of three network meta-analyses:** [Pediatric fluoxetine reanalysis finds a smaller symptom effect after excluding an unreliable outlier](../topics/10_ssri_antidepressants.md#pediatric-fluoxetine-reanalysis-finds-a-smaller-symptom-effect-after-excluding-an-unreliable-outlier). - **2026-09-20 — Human first-in-human randomized crossover preprint; not peer-reviewed:** [Small amygdala-ultrasound study engages its brain target without greater symptom improvement](../topics/10_ssri_antidepressants.md#small-amygdala-ultrasound-study-engages-its-brain-target-without-greater-symptom-improvement). - **2026-10-06 — New formal observational human-study registration; no results:** [Japan registers a study combining digital cognition and blood biomarkers for Alzheimer triage](../topics/08_alzheimers.md#japan-registers-a-study-combining-digital-cognition-and-blood-biomarkers-for-alzheimer-triage). - **2026-10-05 — Sponsor-reported 36 month clinical follow-up/conference results; not full peer-reviewed follow-up:** [PRIMA reports three-year prosthetic visual-acuity benefit in a smaller follow-up group](../topics/18_hearing_vision.md#prima-reports-three-year-prosthetic-visual-acuity-benefit-in-a-smaller-follow-up-group). - **2026-10-01 — Sponsor-reported foreign regulatory filing milestone:** [Japan accepts MOGENRY for priority review; approvals remain pending](../topics/18_hearing_vision.md#japan-accepts-mogenry-for-priority-review-approvals-remain-pending). - **2026-10-06 — Sponsor conference-schedule announcement; not results:** [MCO-010 adds an October 11 four-year RP presentation and dry-AMD poster](../topics/18_hearing_vision.md#mco-010-adds-an-october-11-four-year-rp-presentation-and-dry-amd-poster). - **2026-10-02 — Sponsor-reported EADV observational cross-sectional survey:** [GLP-1 hair survey reports more complaints, without establishing causality](../topics/19_hair_loss.md#note-2026-10-02-scopglp1). - **2026-10-05 — Sponsor conference schedule; results not yet appraised:** [Longer adolescent alopecia-areata follow-up scheduled for October 8–11](../topics/19_hair_loss.md#note-2026-10-05-baricitinib). - **2026-10-05 — Trial-registry completion update:** [Small post-weight-loss micro-coring cohort is completed, without results](../topics/20_skin_aging.md#note-2026-10-05-ellacor). - **2026-09-30 — Retrospective trial registration; no results:** [Separate 12-person exosome/microneedling pilot disclosed after completion](../topics/20_skin_aging.md#note-2026-09-30-anteage). - **2026-10-05 — Trial-registry timing revision:** [SCARFREE verteporfin timeline revised; recruitment still unconfirmed](../topics/21_scars.md#note-2026-10-05-scarfree). - **2026-10-02 — Retrospective clinical-trial disclosure; no results:** [ON101 surgical-scar pilot newly registered after completion](../topics/21_scars.md#note-2026-10-02-on101). - **2026-10-02 — New human study registration; no results:** [Facetem S adds a registered nasolabial-fold follow-up study](../topics/22_facial_volume.md#note-2026-10-02-facetem). - **2026-10-05 — Trial-registry completion update:** [HArmonyCa midface comparison is completed, without posted results](../topics/22_facial_volume.md#note-2026-10-05-harmonyca). - **2026-10-05 — New study registration; no results:** [New RADIESSE study will follow Chinese adults for two years](../topics/22_facial_volume.md#note-2026-10-05-radiesse). - **2026-09-25 — New-to-watch in-window human trial registration:** [FXS5626 adds a registered Phase 2/3 vitiligo program](../topics/23_pigmentation.md#note-2026-09-25-fxs5626). - **2026-07-02 — Historical baseline; Earlier registered human program; baseline addition, not new trial launch:** [Recovered baseline: remibrutinib is being tested for papulopustular rosacea](../topics/24_acne_rosacea.md#note-2026-07-02-remibrutinib). - **2026-10-02 — Official conference randomized-study abstract; full paper not appraised:** [P11-4 abstract reports fluorescence gains without superior visible masking](../topics/25_dental.md#note-2026-10-02-p114). - **2026-09-25 — New-to-watch retrospective trial registration; no results:** [Registered study compares local drugs and micro-osteoperforation for alignment](../topics/25_dental.md#note-2026-09-25-orthodontic). - **2026-10-05 — Retrospective Phase 1/2 trial disclosure; no results:** [Periodontal platelet-fibrin and oxygen-gel pilot registered after completion](../topics/25_dental.md#note-2026-10-05-iprfgel). ## Coverage by topic ### Whole-body MRI **Coverage: partial.** 1 recorded entries; full-topic successful-check date unchanged. **Searches:** whole body MRI screening HERCULES results October 2026 September 2026; whole body MRI September 28 2026 Philip Lacy podcast HERCULES; "whole-body MRI" "October 2026" results screening study **Gaps:** Read current topic/state, searched overlap from September 5 (last full success September 12), prioritizing changes missed at October 2 focused check.; Appraised October 1 JGIM systematic review full primary article, HERCULES official study site, and September 28 Andrew Lacy podcast indexed official show notes.; HERCULES live registry API inaccessible; existing April 2025 status/date snapshot not re-verified. No comprehensive international registry, repeated-round outcomes or full podcast/audio sweep. **Informal sources:** Revisited September 28 mindbodygreen episode668, Andrew Lacy (Prenuvo CEO) with host Jason Wachob. Original show-note indexing specifies an internally derived 5% radiologically suspected potentially life-saving finding claim, not saved lives or mortality benefit; 200k scans is a commercial experience claim. Full page failed; audio unreviewed. October1 Levels #313 official indexed show notes also located, full page failed. No distinct new rumor selected. **Sources checked:** - [Source 1](https://link.springer.com/article/10.1007/s11606-026-10802-y) - [Source 2](https://www.herculesstudy.org/) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06212479) - [Source 4](https://podcasts.apple.com/nl/podcast/what-200k-full-body-scans-reveal-about-how-we-age-andrew/id1246494475?i=1000791846530) - [Source 5](https://www.sciencedirect.com/science/article/pii/S0899707126001993) ### Galleri and organ-specific cancer screening **Coverage: partial.** 1 recorded entries; full-topic successful-check date unchanged. **Searches:** Galleri FDA approval October 2026 September 2026 colorectal screening results; genomic newborn screening polygenic risk pharmacogenomics trial September October 2026 after:2026-09-25 before:2026-10-07 **Gaps:** Read topic/current panel and paper events; searched since September5 with October2–6 emphasis. Opened new October5 GRAIL announcement and current news center.; October5 official sponsor source explicitly still says Galleri not FDA-cleared or approved. This is current verification separate from advisory vote.; EDCC/ESMO actual posters and full FDA meeting transcript not appraised. Organ-specific colorectal registry census and SDC2 full-paper gap remain; no complete-topic no-news conclusion. **Informal sources:** Searched Galleri FDA timing/Reddit. September24 r/EverythingScience discussion repeats advisory vote and uncertainty; September28 r/ProactiveHealth price discussion is access/anecdote. No original new approval deadline or efficacy rumor verified. Existing approval-timing speculation stays unresolved. **Sources checked:** - [Source 1](https://grail.com/news-center/) - [Source 2](https://grail.com/press-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-edcc-and-esmo-congress-2026/) - [Source 3](https://www.fda.gov/media/195032/download) ### GLP-1 and related metabolic therapies **Coverage: partial.** 1 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: obesity GLP-1 trial October2026 retatrutide eloralintide AMPLIFY; 2026-10-06: NEJMoa2604169 PubMed; 2026-10-06: ClinicalTrials.gov LastUpdatePostDate September5–October6; interventional DRUG, obesity/GLP1; first50; 2026-10-06: Reddit EASD EloraTZP, original 1wu5875 claim and Oct5 1wyga38 repost **Gaps:** September5–October6 overlap; prioritize unpublished/recovered September29 TRIUMPH1 and newly registered metabolic trials. First50 recent drug-intervention records inspected; pagination remains. No worldwide safety/access/incretin census or new curve digitization.; Enicepatide NCT06628362 now COMPLETED in October6 record; endpoint timing discrepancy versus sponsor report was not fully reconciled. **Informal sources:** Read original u/Hopeful_Candle_9781 September30 thread and Oct5 r/Eloralintide repost; week31 near30%/future approvals remain unsupported/mixed-study claims. No new efficacy leak promoted. Full EASD Q&A/podcasts not reviewed. **Sources checked:** - [Source 1](https://pubmed.ncbi.nlm.nih.gov/42814954/) - [Source 2](https://www.nejm.org/doi/10.1056/NEJMoa2604169) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07841860) - [Source 4](https://clinicaltrials.gov/study/NCT07841860) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06628362) - [Source 6](https://clinicaltrials.gov/study/NCT06628362) - [Source 7](https://www.reddit.com/r/mounjarouk/comments/1wu5875/eloralintide_tirzepatide_results_are_out_even/) - [Source 8](https://www.reddit.com/r/Eloralintide/comments/1wyga38/easd_2026_the_weight_equation_is_solved_by/) ### Muscle building and preservation **Coverage: partial.** 1 recorded entries; full-topic successful-check date unchanged. **Searches:** https://clinicaltrials.gov/api/v2/studies?query.term=%28myostatin+OR+bimagrumab+OR+enobosarm+OR+%22muscle+preservation%22+OR+deramiocel%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json **Gaps:** Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 22 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. Full BELIEVE post-withdrawal tables and new HOPE-3 long-term harms tables were not recovered; original Cantor webcast remains unreviewed. **Informal sources:** Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT05616013) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07777575) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05156320) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06411288) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06643728) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06901349) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06299098) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06445075) - [Source 9](https://www.capricor.com/investors/news-events/press-releases/detail/356/capricor-therapeutics-presents-positive-hope-3-open-label) - [Source 10](https://clinicaltrials.gov/api/v2/studies?query.term=%28myostatin+OR+bimagrumab+OR+enobosarm+OR+%22muscle+preservation%22+OR+deramiocel%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json) - [Source 11](https://www.lilly.com/hcp/congresses/easd-2026) - [Source 12](https://ir.verupharma.com/news-events/press-releases) ### Longevity and healthspan trials **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: human longevity October2026 rapamycin metformin senolytics trials; 2026-10-06: PEARL24month AgingCell exact paper source-chain follow-up; 2026-10-06: direct NCT07520110/NCT06658093/NCT05835999/NCT07144293/NCT04742777 **Gaps:** September5–October6 overlap plus older program recovery; direct RESTOR, MAVRIC, everolimus and IPACE-HIV records rechecked. No new material efficacy finding in these focused sources; incomplete broad coverage.; AFAR TAME page fetch failed; funded launch cannot be refreshed. AgelessRx Oct5 updated explainer repeats the pilot and does not provide verified larger-trial initiation; no new efficacy event. Full senolytic/mTOR registry census and original audio incomplete. **Informal sources:** Vitaei Apr11 claim revisited and its primary link checked: unrelated2023 cellular-aging paper. October Reddit AMPK items are preclinical and excluded. Full Kaeberlein/Attia/other original podcasts not appraised. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04742777) - [Source 2](https://clinicaltrials.gov/study/NCT04742777) - [Source 3](https://vitaei.com/articles/pearl-rapamycin-trial) - [Source 4](https://doi.org/10.1111/acel.14056) - [Source 5](https://onlinelibrary.wiley.com/doi/10.1111/acel.14056) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07520110) - [Source 7](https://clinicaltrials.gov/study/NCT07520110) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06658093) - [Source 9](https://clinicaltrials.gov/study/NCT06658093) - [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT05835999) - [Source 11](https://clinicaltrials.gov/study/NCT05835999) - [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07144293) - [Source 13](https://clinicaltrials.gov/study/NCT07144293) - [Source 14](https://www.afar.org/tame-trial) - [Source 15](https://agelessrx.com/xprize-healthspan-update-inside-agelessrxs-longevity-clinical-trial/) ### Localized fat removal and cellulite **Coverage: partial.** 0 recorded entries; full-topic successful-check date unchanged. **Searches:** CBL-514 RZL-012 tesamorelin cellulite trial October 2026; cellulite randomized trial October 2026 treatment; site:caliwaybiopharma.com/en/news-detail 2026 October; site:theratech.com tesamorelin September October 2026; ClinicalTrials.gov named programs AND LastUpdatePostDate 2026-09-05 to 2026-10-06; broader regional-fat/cellulite discovery 2026-09-25 to 2026-10-06; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap) **Gaps:** Prior October2 CBL-514 EASD pooled VAT subgroup and September23 first-dose release deduplicated. SUPREME01 remains recruiting320 with July2027 primary/September2027 final estimates; AYP101 completed252, no posted results. Tesamorelin NCT03375788 remains completed51 with old posted results; no new indication asserted. Existing EGRIFTA formulation remains separate from HIV indication.; RZL012 named phase2 records unchanged; no new China NDA filing/readout verified. No new regional-fat or cellulite entrants returned in date-filtered search. Full original EASD tables, SUPREME02 current matched registry, updated global cellulite comparisons, regulator census and rare-harm inventory remain incomplete. Broad EuropePMC discovery failed503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review. **Informal sources:** Targeted Reddit/talk searches found October2–5 CBL514 self-experiment/sourcing threads and tesamorelin/retatrutide anecdotes, excluded from formal-development efficacy. Permalinks searched: https://www.reddit.com/r/Biohacking/comments/1ww4w3j/cbl514/ and https://www.reddit.com/r/BodyHackGuide/comments/1sschiz/does_anyone_have_first_hand_experience_with_cbl514/ . No new attributable formal trial rumor selected; incomplete podcast/full transcript review. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07140939) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT06256445) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT03375788) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT04867434) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05445557) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07608770) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07608757) - [Source 8](https://www.caliwaybiopharma.com/en/news/) - [Source 9](https://www.caliwaybiopharma.com/en/news-detail/-CBL-514-EASD-2026-subcutaneousfat-visceralfat-reduction-study-ENG/) - [Source 10](https://www.theratech.com/medicines-pipeline/medicines/egrifta-sv) ### Broad cardiovascular prevention, lipids and screening **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: lipid lipoprotein cholesterol trial October2026 results; 2026-10-06: NST1024 title PubMed/publisher; 2026-10-06: ClinicalTrials.gov September5–October6 interventional PCSK9/lipoprotein(a)/coronary plaque first50; 2026-10-06: October2026 lipoprotein podcasts; Curbsiders541 **Gaps:** September5–October6 recent registry discovery; first50 records plus direct HEART3/DR10624 statuses and sponsor discovery. Broad search is nonspecific and paginated; no complete Lp(a)/ApoB/prevention-screening census.; COR2003/COR1004 NCT07858019 is a newly registered phase1 lead; target/mechanism not independently verified, so no precise target claim. NST1024 September29 journal publication found, but full primary effect/safety details unavailable; remains coverage gap. COMPETE SWITCH CV original HR orientation/counts remain unresolved. **Informal sources:** Curbsiders Oct5 lipid-guideline episode discovered; page fetch failed and audio not appraised. Recent commentary mainly repeats HORIZON failure. No original new outcome leak verified. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07861100) - [Source 2](https://clinicaltrials.gov/study/NCT07861100) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07853716) - [Source 4](https://clinicaltrials.gov/study/NCT07853716) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07839936) - [Source 6](https://clinicaltrials.gov/study/NCT07839936) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07848880) - [Source 8](https://clinicaltrials.gov/study/NCT07848880) - [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07858019) - [Source 10](https://clinicaltrials.gov/study/NCT07858019) - [Source 11](https://www.lipidjournal.com/inpress) - [Source 12](https://ir.newamsterdampharma.com/news-events/press-releases) - [Source 13](https://thecurbsiders.com/curbsiders-podcast/541-a-walk-through-the-2026-lipid-management-guidelines) ### Alzheimer's screening and therapies **Coverage: partial.** 1 recorded entries; full-topic successful-check date unchanged. **Searches:** AlzheimertherapybiomarkerbloodtestclinicaltrialOctober2026 after:2026-10-01 before:2026-10-07; site:reddit.com "Alzheimer" "October" "2026" trialobicetrapib; site:clinicaltrials.gov "SAR448851"; "SAR448851" NCT phase2 2026 **Gaps:** Read full topic/state. Located and opened October 6 UMIN STRIDE-PAD diagnostic-pathway registration; opened original Attia/Davidson public episode page.; SAR448851 program located via official Canada/EMA leads but live CT.gov shell/API unusable; not promoted as new October initiation based on an aggregator's September 28 date.; Full antibody labels/ARIA/assay recalls and prevention registries not refreshed. Original paid Attia transcript unreviewed; no cognitive-prevention benefit from SPINOZA recruitment. **Informal sources:** Reopened Attia/Davidson public notes; existing Alzheimer-prevention hypothesis remains unconfirmed despite official SPINOZA recruitment. October 5 Reddit high-dose psilocybin case-report claim surfaced but original page failed; no formal new therapy claim promoted. Full paid transcript/Reddit census incomplete. **Sources checked:** - [Source 1](https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071848) - [Source 2](https://peterattiamd.com/michaeldavidson/) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07688213) - [Source 4](https://clinicaltrials.gov/study/NCT07688213) ### Psilocybin and related therapies **Coverage: partial.** 0 recorded entries; full-topic successful-check date unchanged. **Searches:** psychedelic depression anxiety psilocybin trial October2026 after:2026-10-01 before:2026-10-07; site:ir.compasspathways.com "2026" "October"; site:investor.ghres.com "October" "2026"; site:ir.helus.com "October" "2026" clinical; site:ir.definiumtx.com "October" "2026" clinical; "Adverse Health Outcomes of Psilocybin,LSD,MDMA,Ibogaine,and5-MeO-DMT" **Gaps:** Read current topic/state; October 1 Helus legal-name and October 5 Compass office news add no clinical results or approval. Opened FDA hearing page and actual September 29 JAMA public-health survey.; FDA comment deadline October 5 at 23:59 ET elapsed; no new policy/product decision verified. Full hearing recording/transcript and HLP003 posters remain unappraised.; Safety survey appraised as context, not regulated-trial results: mixed/unsupervised use cannot quantify clinical-trial risks. Broad registry/sponsor-call coverage incomplete; no full-topic no-news claim. **Informal sources:** October 2 r/shroomstocks safety-paper thread traced to September 29 JAMA letter, not an October 2 trial. October 3 HLP003/HLP004 prediction thread is investor opinion without new original inside information. October 5 Alzheimer psilocybin case-report claim located but original post failed; excluded from formal therapy findings. Existing Resilient MDMA refiling remains unverified for FDA acceptance. Full podcast/transcript review incomplete. **Sources checked:** - [Source 1](https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026) - [Source 2](https://ir.helus.com/) - [Source 3](https://ir.helus.com/news-releases/news-release-details/helus-pharma-announces-completion-legal-name-change) - [Source 4](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Celebrates-Opening-of-New-U-S--Office-in-Jersey-City-New-Jersey-2026-IF7TAw8tpv/default.aspx) - [Source 5](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2854616) - [Source 6](https://www.reddit.com/r/shroomstocks/comments/1wvzfid/adverse_health_outcomes_of_psilocybin_lsd_mdma/) - [Source 7](https://www.reddit.com/r/shroomstocks/comments/1wwykhy/what_is_everyones_predictions_for_phase_3_for/) ### Mental-health treatments, SSRIs and newer antidepressants **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** antidepressant SSRI depression PTSD OCD clinical trial October2026 after:2026-10-01 before:2026-10-07; "SSRI" "October2026" trialresults; "antidepressant" "October5,2026" trial; "Low-Intensity Focused Ultrasound of the Amygdala in Depression and Anxiety"; site:reddit.com depression antidepressant newtrial fasedienol liafensine October2026; fluoxetine children "2026" "Naudet" "meta" trial reanalysis; "cesm.70108" "-0.26" "-0.23" **Gaps:** Read current topic/state; appraised October 1 pediatric fluoxetine reanalysis full primary paper, September 20 amygdala FUS primary preprint abstract and current informal leads.; FUS is newly recovered recent evidence from the overlap, not an October 6 trial; full medRxiv/PMC pages blocked. SSRIs remain distinct from neuromodulation and ketamine.; All OCD/PTSD/addiction/bipolar registries and labels not refreshed. Perospirone October 2 commentary traced to a 2025 paper, not new news; psychotherapy NCT07857629 lead not promoted without primary appraisal. **Informal sources:** October 4 original r/science fluoxetine post traced to the actual October 1 primary reanalysis; a claim that the 2006 trial created pediatric approval would be unsupported. October 5 Psychiatry emotional-blunting discussion consists of anecdotes/hypotheses, not a new controlled outcome. October 5 clinician glutamatergic video revisits the old Auvelity program; no distinct new development rumor selected. Full talk/podcast coverage incomplete. **Sources checked:** - [Source 1](https://onlinelibrary.wiley.com/doi/10.1002/cesm.70108) - [Source 2](https://pubmed.ncbi.nlm.nih.gov/42824445/) - [Source 3](https://pubmed.ncbi.nlm.nih.gov/42780377/) - [Source 4](https://www.medrxiv.org/content/10.64898/2026.09.18.26363360v1) - [Source 5](https://pmc.ncbi.nlm.nih.gov/articles/PMC13596687/) - [Source 6](https://clinicaltrials.gov/study/NCT05147142) - [Source 7](https://www.reddit.com/r/science/comments/1wxqobu/one_small_2006_trial_of_just_40_kids_in_iran_may/) - [Source 8](https://psychiatryevidencebase.com/perospirone-antidepressant-augmentation-inadequate-response-randomised-trial/) ### Bone health, joint preservation and cartilage repair **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** https://clinicaltrials.gov/api/v2/studies?query.term=%28osteoporosis+OR+%22cartilage+repair%22+OR+lorecivivint+OR+%22TG-C%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json **Gaps:** Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 91 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. ACTiVION-I October readout not verified; full osteoporosis cell-therapy paper and EB613 initiation remain gaps. Lorecivivint EMA forecast now resolved by a retrieved sponsor release. **Informal sources:** Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03203330) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT03868033) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06400862) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05391776) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07806331) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07112443) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT01463813) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT04385303) - [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT04520607) - [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT03291470) - [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT01919164) - [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT02566655) - [Source 13](https://www.streetinsider.com/Globe%2BNewswire/European%2BMedicines%2BAgency%2BValidates%2BBiosplice%E2%80%99s%2BApplication%2Bfor%2BLorecivivint%2B%28LOR%29%2Bin%2BKnee%2BOsteoarthritis%2Band%2BBegins%2BReview/27138267.html) - [Source 14](https://www.biosplice.com/news/default.aspx) - [Source 15](https://clinicaltrials.gov/study/NCT07339111) - [Source 16](https://clinicaltrials.gov/api/v2/studies?query.term=%28osteoporosis+OR+%22cartilage+repair%22+OR+lorecivivint+OR+%22TG-C%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json) ### Liver health and noninvasive assessment **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: MASH trial October2026 lanifibranor efruxifermin pegozafermin; 2026-10-06: ClinicalTrials.gov September5–October6 interventional MASH/NASH first50; 2026-10-06: Wegovy MASH SeptemberCHMP EMA outcome; EPAR current SmPC; 2026-10-06: Reddit OctoberMASH and saved September18 CHMP original **Gaps:** September5–October6 overlap; first50 recent MASH/NASH registry records and direct new ALNCIDEB/AROINHBE protocols read. Efruxifermin/pegozafermin/survodutide ongoing records are not new results. Full cirrhosis/noninvasive test census remains incomplete.; Wegovy EPAR and September21 product information checked: no steatohepatitis indication located. This does not determine the September CHMP variation outcome or infer rejection. NATiV3 Q4 topline remains forecast, no result verified. **Informal sources:** Original September18 u/kiyomoris CHMP-omission inference revisited; current SmPC does not resolve the actual procedure disposition. No approval/rejection inferred. Original full EASL podcasts/talk audio not appraised. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07859813) - [Source 2](https://clinicaltrials.gov/study/NCT07859813) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07854782) - [Source 4](https://clinicaltrials.gov/study/NCT07854782) - [Source 5](https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy) - [Source 6](https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf) - [Source 7](https://www.reddit.com/r/NovoNordisk_Stock/comments/1wjxoxg/wegovys_mash_indication_was_for_adoption_at_chmp/) ### Cancer treatment, vaccines and recurrence prevention **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** cancer vaccine clinical trial oncology results October 2026 after:2026-10-01 before:2026-10-07; site:reddit.com cancer vaccine October 2026 trial results REGAL IDOV2 interpath after:2026-09-25 before:2026-10-07; site:fda.gov drugs oncology "October" "2026" approves; cancer phase3 results September29 October5 2026 trial immunotherapy oncology; "IDOV2" September October2026 clinical trial; "cancer vaccine" "October" "2026" "phase" trial; site:ir.sellaslifesciences.com "August11,2026" "REGAL" **Gaps:** Read current broad-oncology/vaccine topic/state, deduplicated evERA/approvals/INTerpath schedule. Search focusedOctober2–6 plus September5 overlap.; Appraised September24 IMpassion050 final primary abstract and original SELLASAugust11 release; newOctober2 Reddit REGAL timing inference original opened.; Full IMpassion safety appendix inaccessible; broad cellular/radiopharmaceutical/vaccine registry sweep incomplete. ASTEROIDSeptember30 accepted manuscript located but fullpaper failed; IDOV2 literal source remained unmatched. All are gaps, not no news. **Informal sources:** Original October2 Run4theRoses2 REGAL event80 any-day-now post opened; it is extrapolation from aggregate death counts with conspicuous investment promotion, not inside information. Existing September27 REGAL outcome guesses do not independently corroborate it. Source date recovered from indexed original; sponsorAugust11 describes event-triggered analysis with no calendar date. Can record a new clearly labeled speculation item, but do not promote efficacy or approval expectations. **Sources checked:** - [Source 1](https://pubmed.ncbi.nlm.nih.gov/42785163/) - [Source 2](https://pmc.ncbi.nlm.nih.gov/articles/PMC13634523/) - [Source 3](https://www.nature.com/articles/s41467-026-77552-7) - [Source 4](https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications?randparam=286859) - [Source 5](https://ir.sellaslifesciences.com/news/default.aspx) - [Source 6](https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update/default.aspx) - [Source 7](https://www.reddit.com/r/sellasLifescience/comments/1wvlkg6/when_you_add_up_the_dates_below_it_equals_an_80th/) ### Autoimmune disease and immune reset **Coverage: partial.** 1 recorded entries; full-topic successful-check date unchanged. **Searches:** https://clinicaltrials.gov/api/v2/studies?query.term=%28%22CAR+T%22+OR+%22immune+reset%22+OR+fenebrutinib+OR+%22Treg%22%29+AND+%28lupus+OR+myositis+OR+%22multiple+sclerosis%22+OR+%22rheumatoid+arthritis%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json **Gaps:** Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 28 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. No new restart announcement verified for paused rapcabtagene/zolecabtagene; unchanged/pre-pause registry records cannot prove restart. C-CAR168 remains not yet recruiting. Complete long-term CAR-T safety and transcript review incomplete. **Informal sources:** Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06588491) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT06193889) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07729826) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06375993) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06980805) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06154252) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06121297) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06665256) - [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07015983) - [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT04895696) - [Source 11](https://clinicaltrials.gov/study/NCT07855302) - [Source 12](https://clinicaltrials.gov/api/v2/studies?query.term=%28%22CAR+T%22+OR+%22immune+reset%22+OR+fenebrutinib+OR+%22Treg%22%29+AND+%28lupus+OR+myositis+OR+%22multiple+sclerosis%22+OR+%22rheumatoid+arthritis%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json) - [Source 13](https://www.onclive.com/view/car-t-in-autoimmune-disease-and-key-takeaways) ### Non-opioid pain treatments **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** https://clinicaltrials.gov/api/v2/studies?query.term=%28suzetrigine+OR+%22VX-993%22+OR+onzotrigine+OR+%22LTG321%22+OR+%22non-opioid%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json **Gaps:** Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 40 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. Full LTG321/onzotrigine regulatory correspondence, VX-993 detail and all pain-mechanism literature not appraised. **Informal sources:** Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06628908) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07231419) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04570371) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06797869) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05558410) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT05553366) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT05661734) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06696443) - [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT05273749) - [Source 10](https://link.springer.com/article/10.1007/s40122-026-00865-4) - [Source 11](https://clinicaltrials.gov/study/NCT06887959) - [Source 12](https://clinicaltrials.gov/study/NCT07856654) - [Source 13](https://clinicaltrials.gov/api/v2/studies?query.term=%28suzetrigine+OR+%22VX-993%22+OR+onzotrigine+OR+%22LTG321%22+OR+%22non-opioid%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json) ### Kidney preservation and earlier detection **Coverage: partial.** 5 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: kidney trial October2026 results -kidney cancer; 2026-10-06: REMODEL s41591-026-04674-2 primary paper; 2026-10-06: ClinicalTrials.gov September5–October6 CKD/IgAN interventional first50; 2026-10-06: Reddit kidney new trial October2026; SeaStar ASN original release; kidney podcasts **Gaps:** September5–October6 overlap discovery; primary REMODEL paper including null primary outcomes and safety read. First50 recent CKD/IgAN records inspected; pagination/new disease-specific therapies and early detection census incomplete.; Sefaxersen numerical interim/safety disclosure, ORIGIN3 full final safety, EASi-KIDNEY final quantitative analysis remain gaps. New SAVE poster scheduled but not yet reviewed; FDA HDE route and exact indication independently verified; full historical benefit/safety appraisal remains incomplete. **Informal sources:** Oct2 r/SeaStarMedical post repeats sponsor ASN announcement; original sponsor confirms date, not a numerical result. Broader kidney podcast/audio and patient anecdotes not comprehensively appraised. **Sources checked:** - [Source 1](https://www.nature.com/articles/s41591-026-04674-2) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04865770) - [Source 3](https://clinicaltrials.gov/study/NCT04865770) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT07849348) - [Source 5](https://clinicaltrials.gov/study/NCT07849348) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07850752) - [Source 7](https://clinicaltrials.gov/study/NCT07850752) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07857200) - [Source 9](https://clinicaltrials.gov/study/NCT07857200) - [Source 10](https://www.globenewswire.com/fr/news-release/2026/10/02/3373853/0/en/seastar-medical-announces-late-breaking-presentation-at-asn-kidney-week-2026.html) - [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT06926660) - [Source 12](https://clinicaltrials.gov/study/NCT06926660) - [Source 13](https://www.reddit.com/r/SeastarMedical/comments/1wvveon/seastar_medical_announces_latebreaking/) - [Source 14](https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/quelimmune) - [Source 15](https://www.fda.gov/media/176511/download?attachment=) ### Hearing and vision preservation/restoration **Coverage: partial.** 3 recorded entries; full-topic successful-check date unchanged. **Searches:** PRIMA36monthresultsOctober3 2026 EURETINASciencevision; MCO-010geographicatrophyOctober4 2026 EURETINAresults; OPGxBEST1EURETINAOctober4 2026 clinicaldata; "Science" "PRIMA" "October5,2026"; "PRIMA" "36" "29" "2026" Science; "MCO-010" "October" "2026" "atrophy"; "MCO-010" "EURETINA" "2026"; "MCO-010" geographicatrophy "NCT" 2026 randomized; site:reddit.com "hearing" "AC102" "October" "2026" **Gaps:** Read topic/state; followed elapsed EURETINA October 3/4 catalysts. Actual new PRIMA 36-month numerical release opened from Science's Business Wire/AOL syndication; original Business Wire unavailable.; October 1 Japan MOGENRY priority-review and October 6 AAO schedule opened on sponsor site. Inherited RP/IRDs kept separate from acquired AMD/GA.; Actual BEST1 EURETINA PDF now listed on sponsor index, but download returned 403 and local network unavailable. No new numbers inferred. MCO-010 October 4 GA abstract/slides not retrieved; registry unmatched. ARMD observer October 4 notes describe three Stargardt patients, not a verified GA result.; PST-611 actual October 2 presentation, DAYBREAK/BRUNELLO tables and regulator/label/acquired-hearing inventory remain unappraised. AC102 purported-email thread revisited; no official phase 3/tinnitus confirmation; live API failed. **Informal sources:** Original ferttt2 August 29 AC102 purported-email thread opened; conditional 2027 phase 3/tinnitus plans remain unconfirmed, with no proven chronic-tinnitus benefit or authenticated email. PRIMA durability news traces to an actual sponsor release. ARMD observer Stargardt summary does not verify new GA efficacy. Wider podcast/talk sweep incomplete. **Sources checked:** - [Source 1](https://www.aol.com/articles/science-corp-announces-long-term-140000000.html) - [Source 2](https://www.businesswire.com/news/home/20261005144492/en/) - [Source 3](https://euretina.org/vienna-2026/satellite-symposia/) - [Source 4](https://nanostherapeutics.com/news/) - [Source 5](https://nanostherapeutics.com/2026/10/01/nanoscope-therapeutics-announces-pmda-acceptance-and-priority-review-of-new-drug-application-for-mogenry-in-japan-for-the-treatment-of-inherited-retinal-dystrophies/) - [Source 6](https://nanostherapeutics.com/2026/10/06/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting/) - [Source 7](https://ir.opusgtx.com/presentations) - [Source 8](https://d1io3yog0oux5.cloudfront.net/_4469545e1cca264313b28c6faf78be4c/opus/db/601/7994/pdf/Pennesi_Oct%2B2026_BEST1%2BPh%2B1-2%2BCohort%2B1%2BResults_Euretina%2B2026.pdf) - [Source 9](https://armd-france.org/euretina-2026-dernier-jour-derniere-session-novel-therapies/) - [Source 10](https://www.reddit.com/r/tinnitusresearch/comments/1w1vebv/audiocure_ac102_update/) - [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT05776459) ### Hair loss, restoration and graying **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** PP405 ABS-201 clascoterone VDPHL01 October 2026 hair trial; PP405 ABS-201 KX-826 GT20029 BQ-002 October 2026; bempikibart alopecia areata EADV October 2026 upadacitinib; site:reddit.com greyhairreversal BQ002 BioCopper October 2026; ClinicalTrials.gov alopecia/hair-graying updated September25–October6 plus named-program September5–October6 overlap; milk-derived MEV-miRNA gel October2026 randomized trial methods; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap) **Gaps:** PP405 Oct2 recruiting milestone already captured October3, not re-alerted. HEADLINE ABS201 unchanged recruiting; phase1/2 metadata remains distinct from phase1 safety evidence. BioCopper remains not yet recruiting88, November2026 start and July2027 completion estimates. Bempikibart and Olumiant September events deduplicated.; New-to-watch Olistic NCT07484061 (March19 registration, updatedOct6, recruiting40; GLP1/GIP users, six-month randomized supplement/placebo) is a baseline lead, not demonstrated treatment. Full current Cosmo/Kintor/Veradermics and AA conference/regulator refresh remains incomplete.; October1 milk-exosome/miRNA plus iSFRP1 gel RCT lead: indexed original describes40 randomized,39 completed,12weeks, short-term trichoscopic gains. Original HTML/PDF/XML returned403/429; full tables, adjusted effect intervals, funding and harms could not be appraised. Methods also call randomized intervention an unregistered observational investigation. Do not promote as a settled efficacy finding. URL attempted: https://www.mdpi.com/2079-9284/13/5/261 . EuropePMC503 prevented broad paper census.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review. **Informal sources:** BQ002 saved rumor re-opened with original Reddit/BioQ: candidate exists, but matched human trial and2027 start remain unconfirmed; no new status alert. PP405 saved September claim remains only partly corroborated by official Oct2 recruiting status/September21 actual start; earlier email/individual dosing unverified. Oct4 r/tressless thread (https://www.reddit.com/r/tressless/comments/1wxeah3/its_q3_2026_where_are_we_at_with_the_novel/) contains speculative PP405-is-dead assertions tied to alleged chemistry and graymarket self-experiment, without an official discontinuation source; current trial remains recruiting. Original thread open failed, indexed text only; no rumor selected. Clascoterone launch rumor not fully reappraised. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07819435) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07317544) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06393452) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05910450) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05914805) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06724614) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06972264) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06018428) - [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07839494) - [Source 10](https://www.pierre-fabre.com/en/news/scop-glp1-study-hair-loss-obesity-diabetes) - [Source 11](https://investor.lilly.com/node/55016/pdf) - [Source 12](https://pelagepharma.com/press-releases/) - [Source 13](https://www.bioq.com/) - [Source 14](https://www.reddit.com/r/greyhairreversal/comments/1t0k55l/bioq_is_developing_an_injectable_drug_bq002/) ### Skin aging, laxity and regeneration **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** KB304 skin rejuvenation clinical trial October2026 radiofrequency; skin rejuvenation laxity randomized October2026 clinical trial; skin rejuvenation microneedling October2026 FDA safety; skin rejuvenation podcast October2026 KB304 trial; ClinicalTrials.gov skin-aging/rejuvenation/laxity/wrinkles updatedSeptember25–October6; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap) **Gaps:** KB304 remains active not recruiting, stale estimated July2025 completion; no new Phase2 start verified. RF-microneedling FDA communication still datedOctober15,2025, ongoing evaluation; not a new2026 alert. Existing polynucleotide and biosome reports deduplicated.; L’Oreal R0090948A NCT07853027 firstpostedOct1, planned13, not yet recruiting; mitochondria/UV stress markers not visible durable rejuvenation. Lower-priority registry lead, no news efficacy. Broad paper search failed503; new Sept22 multimodal RF RCT PMID42766316 abstract not fully fetched/appraised; global device clearance and procedure comparative/rare-safety review incomplete.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review. **Informal sources:** October2 unPAUSED MaryClaireHaver skin-treatment episode show-description/timestamps found (https://podfollow.com/unpaused-with-dr-mary-claire-haver/episode/fe943932b44edaffd4043acbd9653c7879ccb100/view), but full original open failed and audio/transcript not appraised; no specific trial milestone verified. Saved Sept29 Lufkin/Durairaj rapalog/GLP1-face episode direct Buzzsprout fetch failed; no new clinical claim adopted. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06724900) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07849556) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06477172) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT07790237) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07224880) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07849205) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07853027) - [Source 8](https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication) ### Scar prevention, treatment and stretch marks **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** SNT9465 verteporfin stretchmarks scar October2026 clinical trial; scar keloid stretchmark verteporfin October2026 trial; site:reddit.com verteporfin SCARFREE October2026 trial; ClinicalTrials.gov scar/keloid/striae updatedSeptember25–October6; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap) **Gaps:** October1 Syntara expansion/tolerability/null-clinical-signal already recorded; no new efficacy. Geneva verteporfin remains not yet recruiting with stale2026 estimates; siSPARC unknown/staleJune2024. SCARFREE primary update corrects misleading mirror timing.; New registry disclosure ON101 contains structured/narrative inconsistencies. Other low-priority new records: NCT07849010 skinclosure25 recruiting (Sep30); NCT07850557 pressure in burn amputees12 not yet recruiting (Sep30). No results. Full stretchmark comparative trials, matched Syntara IDs and rare harms remain incomplete; EuropePMC503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review. **Informal sources:** Targeted original saved Aug26 r/verteporfin thread (https://www.reddit.com/r/verteporfin/comments/1vypnsk/verteporfin_status_upcoming_trials_and/) re-found: its assertions of ongoing formal trials are not verified by stale NYR Geneva/SCARFREE records. Sept23 off-label-testing comment in https://www.reddit.com/r/ReverseRhinoplasty/comments/1uf4elm/healing_wounds_with_reduced_scarring_verteporfin/ describes personal physician-assisted testing, not a new regulated-trial result. No new formal-program rumor selected; full investor recordings not reviewed. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06944249) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07488988) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06138964) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05461755) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07854470) ### Facial volume restoration and contour **Coverage: partial.** 3 recorded entries; full-topic successful-check date unchanged. **Searches:** facial filler fatgraft trial October2026 volume restoration FDA; facialvolume filler Radiesse October2026 trial approval; site:reddit.com facialcontours filler September2026 Adipeau; ClinicalTrials.gov facial-volume/filler/fatgraft updatedSeptember25–October6; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap) **Gaps:** Macrofat NCT07805889 unchanged recruiting400, Dec10,2026/Mar1,2027 estimates; no results. GLP1-Radiesse NCT07419854 recruiting, no results. New Facetem/Radiesse registries and HArmonyCa completion appraised.; RHA4 active-comparator full paper newly accessed is August2026 historical context, not October news:201 total,173 primary PP; at8weeks mean change-1.3 both arms, CI difference[-0.22,0.25], prespecified0.5 noninferiority margin. Sponsored and mostly women; no superiority/rare-harm inference. FDA exact new product/indication PMA census and global rare/delayed filler safety incomplete; EuropePMC503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review. **Informal sources:** Saved Sept30/Oct1 Adipeau brand-contour post (https://www.reddit.com/r/u_Adipeau/comments/1wubdvg/restoring_facial_contours_without_filler_where/) remains promotion rather than a new controlled outcome; original fetch failed. Saved Lufkin/KayDurairaj episode (https://www.buzzsprout.com/1848150/episodes/19344405-ozempic-face-why-weight-loss-can-make-you-look-older-kay-durairaj-md?t=0) failed direct open; no full transcript/timestamp claim adopted. October5 physician AMA located but not fully appraised; anecdotal technique comments not treated as trial results. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07805889) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07419854) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06351358) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT04769193) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07855224) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07032597) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07856797) - [Source 8](https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/fda-approved-dermal-fillers) - [Source 9](https://pmc.ncbi.nlm.nih.gov/articles/PMC13481993/) ### Pigmentation and uneven skin tone **Coverage: partial.** 1 recorded entries; full-topic successful-check date unchanged. **Searches:** vitiligo povorcitinib ruxolitinib EADV October2026 melasma trial; vitiligo melasma treatment EADV October2026; FXS5626 vitiligo; melasma post-inflammatory randomized September2026; ClinicalTrials.gov melasma/vitiligo/hyperpigmentation updatedSeptember25–October6; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap) **Gaps:** VitiUp Oct1 extension/UVB findings already captured. STOP-V1/V2 original APIs unchanged active not recruiting with no posted results,467/450 actual; DelVito unchanged. FXS5626 registration newly recovered.; Full Incyte EADV P2467/P1780/P2463 actual posters still not retrieved; do not mark scheduled presentations as reviewed results. Broad melasma/PIH/solar-lentigine original-paper census, KT939 protocol and current regulator/action sweep incomplete; EuropePMC503. Fosun Sept8 primary release indexed text found but direct open failed; FXS registration itself was actually downloaded.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review. **Informal sources:** Targeted Reddit/postcast searches found Oct3 upadacitinib use/access anecdotes (https://www.reddit.com/r/Vitiligo/comments/1ww9d49/upadacitinib_update/) and older vitiligo pipeline recaps; no new attributable trial/approval forecast selected. Personal OTC/Rx overseas access anecdotes do not establish U.S. approval. Full original audio not reviewed. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06118411) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07820098) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06113445) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06113471) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07840820) ### Acne and rosacea **Coverage: partial.** 1 recorded entries; full-topic successful-check date unchanged. **Searches:** denifanstat AURORA acne rosacea October2026 trial; site:sagimetbiosciences.gcs-web.com AURORA denifanstat October2026; acne rosacea clinicaltrial October2026 remibrutinib; rosacea remibrutinib trial2026; ClinicalTrials.gov acne/rosacea updatedSeptember25–October6; denifanstat AND acne all records; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap) **Gaps:** AURORA October screening remains sponsor forecast; current denifanstat+acne registry query yields only two Chinese completed studies, no matched U.S. AURORA study. Sept30 extension already captured; Oct1 financing is not clinical efficacy/initiation. Existing RF acne/rosacea redness records unchanged; SP0268 full current API not refreshed in this batch.; Remibrutinib PPR baseline recovered with original registry and HealthCanada protocol. New NCT07854418 Winona postacne-erythema retrospective study80 completed has internally differing narrative/structured schedules and no results; cosmetic care lead not promoted. Full acne/rosacea antibiotic/resistance/device/ocular/redness coverage and EADV data/safety-regulator census incomplete; EuropePMC503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review. **Informal sources:** Targeted Reddit searches yielded individual rosacea treatment stories and Oct4 UK Finacea shortage complaints (https://www.reddit.com/r/Rosacea/comments/1wxaxy3/finacea_out_of_stock_everywhere_uk/), without verified manufacturer/supply statement. Do not extrapolate to U.S. shortage. Sagimet Sept30 webcast replay/supporting slides are listed on original events page; Q&A/audio not appraised. No new rumor selected. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06248008) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07521462) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07805655) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06952517) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07681271) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07854418) - [Source 7](https://clinical-trials-search.canada.ca/en/clinical-trial/501404-rosacea) - [Source 8](https://sagimetbiosciences.gcs-web.com/investor-relations/) - [Source 9](https://sagimetbiosciences.gcs-web.com/events-and-presentations) - [Source 10](https://sagimetbiosciences.gcs-web.com/news-releases/news-release-details/sagimet-announces-positive-full-52-week-results-license-partner) ### Dental alignment, regeneration and repair **Coverage: partial.** 3 recorded entries; full-topic successful-check date unchanged. **Searches:** Toregem TRG035 October2026 dental aligners randomized trial toothregeneration; dental orthodontic enamel periodontal randomized trial October2026; P11-4 Bonchev45 randomized trial enamel2026; Bonchev NCT06749977 publication; ClinicalTrials.gov alignment/repair/regeneration updatedSeptember25–October6; Root-discovered NCT07859358 original primary API retrieval; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap) **Gaps:** September24 printed-aligner paper already captured. NCT07496892 remains NYR with stale March27 record and elapsed September completion estimates; no completion presumed. OrthoPulse records remain completed/noresults or unknown/stale. Toregem Oct2 global startup support and Oct6 BioJapan booth announcements add no first-dosing or efficacy verification; phaseIIa August17 trial-notification remains separate from approval.; New P114 official conference abstract and matching original record appraised. Additional new orthodontic registrations disclose historical completed bracket/laser/ultrasound studies without results; no efficacy selected. Full printed-aligner/root/gum/retention papers, Japanese jRCT PhaseIIa primary record and broad repair/regeneration census remain unappraised; EuropePMC503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review. **Informal sources:** Saved toothregrowth Reddit repost (https://www.reddit.com/r/Biohackers/comments/1wq1adh/910_dentists_probably_wont_recommend_this/) still repeats earlier2030 forecasts and extrapolation to adult missing teeth. Current sponsor business announcements do not confirm that forecast. Targeted informal/podcast search found no new attributable formal milestone; full audio and original-comment census incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06685029) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07496892) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT02954133) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05361616) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06749977) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07842120) - [Source 7](https://sciforum.net/paper/34045) - [Source 8](https://toregem.co.jp/en/archives/category/news) - [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07859358) ### Allergy and airway disease **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** https://clinicaltrials.gov/api/v2/studies?query.term=%28asthma+OR+COPD+OR+%22food+allergy%22+OR+%22chronic+sinusitis%22%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json **Gaps:** Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 120 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. No fuller rademikibart absolute event/safety table or verified VIASKIN filing-acceptance target recovered. Sinus-disease and guideline survey incomplete. **Informal sources:** Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06940154) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05741476) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06940141) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05276570) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07241546) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT03881696) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07675811) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT04851964) - [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT05166889) - [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT05158387) - [Source 11](https://pubmed.ncbi.nlm.nih.gov/42816128/) - [Source 12](https://doi.org/10.1111/all.70531) - [Source 13](https://clinicaltrials.gov/study/NCT07858123) - [Source 14](https://clinicaltrials.gov/api/v2/studies?query.term=%28asthma+OR+COPD+OR+%22food+allergy%22+OR+%22chronic+sinusitis%22%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json) ### Infectious-disease prevention and treatment **Coverage: partial.** 3 recorded entries; full-topic successful-check date unchanged. **Searches:** https://clinicaltrials.gov/api/v2/studies?query.term=%28antibiotic+OR+bacteriophage+OR+vaccine+OR+antiviral%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json **Gaps:** Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 282 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. VYD2311 efficacy remains blinded/pending; AP-SA02 phase 3 actual initiation and REPhRAME formal protocol not verified. Full new-antibiotic/access census incomplete. **Informal sources:** Reddit VAX-31 threads mostly repeat the release and infer approval/market timing; no separate rumor promoted. Saved VYD2311 October safety/titer forecast remains separate from blinded efficacy. Phage anecdotes are not controlled evidence; broader podcast/talk review incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07655180) - [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT07298434) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07326540) - [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT07431307) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT03806166) - [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07214311) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT03959527) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT04979806) - [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT05184764) - [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07047716) - [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT06602024) - [Source 12](https://www.globenewswire.com/de/news-release/2026/10/05/3374299/0/en/vaxcyte-reports-positive-topline-data-from-opus-1-the-pivotal-adult-phase-3-trial-of-vax-31-the-company-s-31-valent-pneumococcal-conjugate-vaccine-candidate.html) - [Source 13](https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex992.htm) - [Source 14](https://clinicaltrials.gov/study/NCT07284654) - [Source 15](https://clinicaltrials.gov/study/NCT07858916) - [Source 16](https://clinicaltrials.gov/study/NCT07860216) - [Source 17](https://clinicaltrials.gov/api/v2/studies?query.term=%28antibiotic+OR+bacteriophage+OR+vaccine+OR+antiviral%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json) ### Genetic screening and risk prediction **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** genomic screening polygenic risk pharmacogenomics newborn embryo October 2026 clinical trial; genetic screening embryo polygenic October 2026 trial Nucleus after:2026-09-25 before:2026-10-07; "genetic" "September 2026" "October 2026" "clinical utility" newborn polygenic trial; site:reddit.com genetic screening embryo polygenic Nucleus October 2026; site:reddit.com Nucleus Vitruvian 14 IQ September October 2026 **Gaps:** Read current genetics/PGT-P notes and state. October5 BeSolveRD primary full paper appraised. Reopened Nucleus official Labs and newly found original September whitepaper.; Recovered direct social permalink through existing Reddit post; X403, original post not independently verified. Whitepaper closes important model-method and ancestry gaps without establishing observed offspring benefit.; Live Nucleus NCT07841769 and T1D NCT07802496 APIs inaccessible; elapsed estimated start not verified. Full newborn/carrier/cascade/PGx inventory incomplete; whitepaper is recovered baseline, not newOctober6 model launch. **Informal sources:** Original September27 Reddit reproducing Kian Sadeghi/Nucleus claim revisited; direct X permalink recovered but403. Sponsor whitepaper gives14.3-point modeled highest-lowest spread with10 European-ancestry embryos, top-vs-average gain half that, not generic14point observed gain. Existing stable key nucleus_vitruvian_2026-09-27_IQ_claim remains unconfirmed as worded; sources/methods clarified, no repeated alert or offspring benefit claim. **Sources checked:** - [Source 1](https://link.springer.com/article/10.1186/s13073-026-01771-2) - [Source 2](https://clinicaltrials.gov/study/NCT07051213) - [Source 3](https://mynucleus.com/labs) - [Source 4](https://mynucleus.com/labs/traits-whitepaper) - [Source 5](https://www.reddit.com/r/singularity/comments/1wrq633/introducing_vitruvian_a_genetic_optimization/) - [Source 6](https://x.com/KianSadeghi5/status/2101018839412531231) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07841769) - [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07802496) ### Insomnia **Coverage: partial.** 3 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: daridorexant daytime-function study October2026; direct named-drug registry search (30latest); 2026-10-06: insomnia digital CBT trial SeptemberOctober2026, PubMed42623797; 2026-10-06: Reddit DARIDREAM/insomnia trial leads **Gaps:** Pending condition baseline partially refreshed across preceding90days, new DARI-DREAM protocol, COMISA and older digital pilot. Existing ten-drug baseline and digital meta-analysis retained; no completed comprehensive baseline.; Full DARI-DREAM protocol/daytime-label intent and actual dosing remain unverified; full digital-pilot text blocked, PubMed XML read. Device/new-drug/digital worldwide census and original podcast sweep incomplete. **Informal sources:** No noteworthy attributable DARI-DREAM leak found; personal medication/CBTi discussion is not trial efficacy. Podcast recordings and all trial-participant threads incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07843329) - [Source 2](https://clinicaltrials.gov/study/NCT07843329) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07743931) - [Source 4](https://clinicaltrials.gov/study/NCT07743931) - [Source 5](https://pubmed.ncbi.nlm.nih.gov/42623797/) - [Source 6](https://doi.org/10.1016/j.sleep.2026.109222) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT05423717) - [Source 8](https://clinicaltrials.gov/study/NCT05423717) ### Obstructive sleep apnea **Coverage: partial.** 1 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: sleep apnea AD109 October2026 podcast/newresults; 2026-10-06: TRIUMPH1 primary PubMed, NCT05813275 postedresults, NCT07225686 protocol; 2026-10-06: OSA oral-appliance podcast October2 and recent Reddit apnea **Gaps:** Inherited October3 diagnostic/treatment baseline retained; TRIUMPH1 publication cross-linked, AD109 primary results record and MARITIME OSA protocol read. Broad device/diagnostic/new-drug baseline still partial.; Full AD109/TRIUMPH1 supplements and comparative safety/durability not independently reappraised. PAP/oral-appliance/surgical stimulation/validated wearable discovery census incomplete. **Informal sources:** AADSM OpenAirWaves Oct2 oral-appliance/OMT episode discovered, page fetch failed and full audio not reviewed. Personal device experiences excluded as efficacy. No verified new AD109 rumor. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07225686) - [Source 2](https://clinicaltrials.gov/study/NCT07225686) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05813275) - [Source 4](https://clinicaltrials.gov/study/NCT05813275) - [Source 5](https://pubmed.ncbi.nlm.nih.gov/42814954/) - [Source 6](https://aadsm.oasis-lms.com/Public/Catalog/Details.aspx?id=V5F9OEaNsKRT3sdXJ4HmAQ%3D%3D) ### Narcolepsy & excessive sleepiness **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: narcolepsy orexin agonist SeptemberOctober2026 Centessa ORX750 TAK360; registry query30latest; 2026-10-06: cleminorexton SAPPHIRE direct NCT07598708; 2026-10-06: oveporexton DEA FederalRegister scheduling and official product page; 2026-10-06: original Orzeyful waiting room RedditSep24 **Gaps:** Pending condition baseline partially expanded with cleminorexton aliases/SAPPHIRE/CRYSTAL1, TAK360 and direct alixorexton/Vibrance3 status. Sources cover earlier90days and older pivotal context selectively.; Orzeyful sponsor page still says expected byNovember pendingDEA; final official DEA action not established. Established oxybate/stimulant/solriamfetol/pitolisant full label and new-program safety census incomplete. Centessa annual-report PDF exceeded webtool size; no numerical new efficacy/safety claims drawn from it. **Informal sources:** Sep24 r/Narcolepsy thread by Dobby_1235 repeats November forecast; a Requiredmetrics comment describes local TAK360 trial eligibility, not evidence of a new milestone. Exact comment times are not reliable from relative rendered labels; source original indexedSep24. Anecdotes are not efficacy or safety rates. Full conference/podcast recordings incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07598708) - [Source 2](https://clinicaltrials.gov/study/NCT07598708) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06752668) - [Source 4](https://clinicaltrials.gov/study/NCT06752668) - [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06952699) - [Source 6](https://clinicaltrials.gov/study/NCT06952699) - [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06812078) - [Source 8](https://clinicaltrials.gov/study/NCT06812078) - [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07646678) - [Source 10](https://clinicaltrials.gov/study/NCT07646678) - [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT06843590) - [Source 12](https://clinicaltrials.gov/study/NCT06843590) - [Source 13](https://www.orzeyful.com/) - [Source 14](https://www.reddit.com/r/Narcolepsy/comments/1wpch72/orzeyful_waiting_room/) ### Circadian rhythm disorders **Coverage: partial.** 2 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: circadian shift-work SeptemberOctober2026 clinicaltrials tasimelteon; 2026-10-06: tasimelteon July20 hearing2026 FDA docket query; 2026-10-06: circadian-condition interventional registry30latest; direct NCT04652882/NCT06568367; 2026-10-06: RedditDSPD/N24 SeptemberOctober2026; seasonal Hetlioz experience **Gaps:** Pending condition baseline partially expanded by DSWPD tasimelteon and SUSTAIN shift-work trials; latest30 circadian registry records screened with irrelevant mechanistic/consumer studies excluded.; Tasimelteon jet-lag prehearing July20 outcome/newdate not verified; FDA hearingnotice only. Timed light/dark/melatonin disorder-specific trials and pediatric/shiftwork broad baseline remain incomplete. SUSTAIN sponsor readout timing not freshly retrieved; registry completion is only an estimate. **Informal sources:** Sep11 r/N24 seasonal Hetlioz personal-experience lead surfaced, directpage fetch failed; no clinical development rumor promoted. No original circadian podcast/talk recording appraised. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04652882) - [Source 2](https://clinicaltrials.gov/study/NCT04652882) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06568367) - [Source 4](https://clinicaltrials.gov/study/NCT06568367) - [Source 5](https://www.govinfo.gov/content/pkg/FR-2026-06-03/pdf/2026-11046.pdf) - [Source 6](https://www.reddit.com/r/N24/comments/1wd1smj/does_anyone_notice_hetlioz_working_differently/) ### Restless legs syndrome **Coverage: partial.** 3 recorded entries; full-topic successful-check date unchanged. **Searches:** 2026-10-06: RLS SeptemberOctober2026 trial iron perampanel Nidra; 2026-10-06: RLS interventional registry30latest; NCT07822607/NCT07675109; 2026-10-06: September16 venousRFA original abstract; AASM2025guideline; 2026-10-06: RedditRestlessLegs Oct3Nidra and trial publication anecdotes **Gaps:** Pending condition baseline partially expanded beyond Nidra with IViron randomized timing trial, XD-TOMAC and controlled/observational discovery. Latest30RLS interventional records screened; important older drug/iron trials, guidance and safety still need full reconciliation.; September16 venous-ablation full methods/harms remain inaccessible. AASM2025guideline indexed primary text reviewed, directPMC returned recaptcha; full guideline/label baseline not complete. ConferenceSOS2026fulltalks and original podcasts not appraised. **Informal sources:** Read Oct3 original Only-The-ShadowKnows thread: mixed personal drug/device experiences and anonymous comments predicting Stanford-study publication; no attributable source/date for a new formal readout, so no efficacy/launch rumor promoted. OriginalSOS2026talks/audio not reviewed. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT07822607) - [Source 2](https://clinicaltrials.gov/study/NCT07822607) - [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07675109) - [Source 4](https://clinicaltrials.gov/study/NCT07675109) - [Source 5](https://journals.sagepub.com/doi/10.1177/02683555261490768) - [Source 6](https://www.reddit.com/r/RestlessLegs/comments/1wwry8s/anything_else_i_might_try/) - [Source 7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11701286/) ## Homepage review and publication The October 3 EloraTZP feature remains useful: randomized active-comparator evidence with matching-arm tolerability. It is retained rather than rotating after three days. No historical plotted values, curves or research dates are changed by export. Only affected histories/frontier/reference details are refreshed. This background run skips user-facing browser preview; validators and native deployment status provide separate checks. The website publication receipt is kept in state.json after successful publication.